[go: up one dir, main page]

MA71628A - Anticorps anti-gpnmb et leurs méthodes d'utilisation - Google Patents

Anticorps anti-gpnmb et leurs méthodes d'utilisation

Info

Publication number
MA71628A
MA71628A MA71628A MA71628A MA71628A MA 71628 A MA71628 A MA 71628A MA 71628 A MA71628 A MA 71628A MA 71628 A MA71628 A MA 71628A MA 71628 A MA71628 A MA 71628A
Authority
MA
Morocco
Prior art keywords
methods
gpnmb antibodies
gpnmb
antibodies
Prior art date
Application number
MA71628A
Other languages
English (en)
Inventor
Andrew PINCETIC
Wei-Hsien Ho
Daniel P. BERMINGHAM
Angie Grace YEE
Marina Roell
Marjorie BATEMAN
Meer Kamal MUSTAFA
Christopher James WEDELES
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of MA71628A publication Critical patent/MA71628A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA71628A 2022-07-29 2023-07-28 Anticorps anti-gpnmb et leurs méthodes d'utilisation MA71628A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263369890P 2022-07-29 2022-07-29
US202363514318P 2023-07-18 2023-07-18
PCT/US2023/071195 WO2024026447A1 (fr) 2022-07-29 2023-07-28 Anticorps anti-gpnmb et leurs méthodes d'utilisation
EP23761697.4A EP4561703A1 (fr) 2022-07-29 2023-07-28 Anticorps anti-gpnmb et leurs méthodes d'utilisation

Publications (1)

Publication Number Publication Date
MA71628A true MA71628A (fr) 2025-05-30

Family

ID=87845501

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71628A MA71628A (fr) 2022-07-29 2023-07-28 Anticorps anti-gpnmb et leurs méthodes d'utilisation

Country Status (12)

Country Link
US (1) US20250270343A1 (fr)
EP (1) EP4561703A1 (fr)
JP (1) JP2025527204A (fr)
KR (1) KR20250043488A (fr)
CN (1) CN119866348A (fr)
AU (1) AU2023314795A1 (fr)
CA (1) CA3261512A1 (fr)
IL (1) IL317690A (fr)
MA (1) MA71628A (fr)
MX (1) MX2025000790A (fr)
TW (1) TW202415679A (fr)
WO (1) WO2024026447A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025166042A1 (fr) 2024-01-31 2025-08-07 Alector Llc Domaines de liaison à l'antigène cd98hc et leurs utilisations
WO2025166040A1 (fr) 2024-01-31 2025-08-07 Alector Llc Protéines de liaison multi-spécifiques qui se lient à gpnmb et à une cible de barrière hémato-encéphalique et procédés pour les utiliser

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (fr) 1990-12-03 2003-02-04 Lisa J. Garrard Methode d'enrichissement de proteines variantes aux proprietes liantes alterees
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (fr) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab') 2?
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US6812002B2 (en) 2000-08-30 2004-11-02 Pfizer Inc. Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US7115265B1 (en) 2001-05-14 2006-10-03 Duke University Four genetic tumor markers specific for human glioblastoma
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
CA2481837A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
EP1498485A4 (fr) 2002-04-09 2006-09-06 Kyowa Hakko Kogyo Kk Cellules a genome modifie
WO2003085102A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
WO2006071441A2 (fr) * 2004-11-30 2006-07-06 Curagen Corporation Anticorps dirigés contre la gpnmb et leurs utilisations
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8039593B2 (en) 2005-10-31 2011-10-18 Duke University Antibodies and immunotoxins that target human glycoprotein NMB
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
AR060871A1 (es) 2006-05-09 2008-07-16 Genentech Inc Union de polipeptidos con supercontigos optimizados
WO2008133641A2 (fr) 2006-10-11 2008-11-06 Curagen Corporation Anticorps dirigés contre la gpnmb et leurs utilisations
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US20130156784A1 (en) 2008-08-20 2013-06-20 Michael Jeffers Compositions Using Antibodies Directed To GPNMB And Uses Thereof
EP2453919A1 (fr) 2009-05-20 2012-05-23 Celldex Therapeutics, Inc. Anticorps dirigés contre gpnmb et utilisations de ceux-ci
US10517948B2 (en) 2015-03-11 2019-12-31 The Board Of Regents Of The University Of Texas System Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
EP3350225A1 (fr) * 2015-09-14 2018-07-25 Spring Bioscience Corporation Anticorps anti-gpnmb et leurs utilisations diagnostiques
KR20200010429A (ko) 2017-05-23 2020-01-30 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
CN110038116B (zh) 2018-01-15 2020-11-20 武汉大学 人肝脏分泌蛋白gpnmb或其拮抗剂或激动剂的用途
EP4003519A2 (fr) * 2019-07-31 2022-06-01 Alector LLC Anticorps anti-ms4a4a et leurs procédés d'utilisation

Also Published As

Publication number Publication date
MX2025000790A (es) 2025-03-07
US20250270343A1 (en) 2025-08-28
CN119866348A (zh) 2025-04-22
TW202415679A (zh) 2024-04-16
AU2023314795A1 (en) 2025-03-06
JP2025527204A (ja) 2025-08-20
IL317690A (en) 2025-02-01
WO2024026447A1 (fr) 2024-02-01
EP4561703A1 (fr) 2025-06-04
KR20250043488A (ko) 2025-03-28
CA3261512A1 (fr) 2024-02-01

Similar Documents

Publication Publication Date Title
MA56074A (fr) Anticorps contre le sars-cov-2 et leurs procédés d'utilisation
MA52390A (fr) Anticorps anti-coronavirus et procédés d'utilisation
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d'utilisation
EP4004051A4 (fr) Anticorps immunomodulateurs et leurs méthodes d'utilisation
EP4346788A4 (fr) Compositions entactogènes énantiomères et leurs méthodes d'utilisation
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP3826612A4 (fr) Nouveaux anticorps monoclonaux spécifiques à cldn 18.2 et leurs méthodes d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA71628A (fr) Anticorps anti-gpnmb et leurs méthodes d'utilisation
EP4211240A4 (fr) Polypeptides effecteurs crispr-cas et leurs méthodes d'utilisation
EP3743109A4 (fr) Anticorps anti-mica/b et leurs méthodes d'utilisation
MA53492A (fr) Anticorps anti-cd33 et leurs méthodes d'utilisation
EP4229063A4 (fr) Nouveaux inhibiteurs de la pikfyve et leurs méthodes d'utilisation
EP4237005A4 (fr) Anticorps anti-transthyrétine et méthodes d'utilisation associées
MA52014A (fr) Anticorps anti-klk5 et méthodes d'utilisation
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d'utilisation
EP4347637A4 (fr) Protéines trispécifiques ciblant dll3 et méthodes d'utilisation
EP3836966A4 (fr) Anticorps catalytiques et leurs méthodes d'utilisation
EP4061848A4 (fr) Anticorps anti-ror-2 et méthodes d'utilisation
MA53328A (fr) Anticorps anti-siglec-5 et leurs procédés d'utilisation
EP3938400A4 (fr) Anticorps cd22 et leurs procédés d'utilisation
EP4138858A4 (fr) Molécules bifonctionnelles et leurs méthodes d'utilisation
MA50958A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation
EP3867271A4 (fr) Formulations d'anticorps anti-rsv et leurs procédés d'utilisation
EP3740509A4 (fr) Anticorps anti-pd-l1 et méthodes d'utilisation